Antiangiogenic gene therapy with VB111 is active in glioblastoma xenografts

被引：1
|
作者：
Brenner, Andrew J. [1 ]
Rogge, Jessica [1 ]
Cohen, Yael [2 ]
Breitbart, Eyal [2 ]
Livnat, Bangio [2 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[2] Vasc Biogen, Tel Aviv, Israel
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-5400
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5400
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Antivascular activity of VB111 in glioblastoma xenografts
    Brenner, A. J.
    Cohen, Y.
    Breitbart, E.
    Rogge, J.
    Giles, F. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] VB-111 Antiangiogenic gene therapy
    Gonzalez, A. N.
    Barmakian, P. M.
    Penson, R. T.
    [J]. DRUGS OF THE FUTURE, 2015, 40 (08) : 523 - 528
  • [3] Phase I/II dose-escalation study of VB-111, an antiangiogenic gene therapy, in patients with recurrent glioblastoma multiforme.
    Brenner, Andrew Jacob
    Cohen, Yael
    Vredenburgh, James J.
    Peters, Katherine B.
    Breitbart, Eyal
    Bangio, Livnat
    Sher, Naamit
    Harats, Dror
    Wen, Patrick Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Antiangiogenic Therapy for Glioblastoma
    Gerstner, Elizabeth R.
    Batchelor, Tracy T.
    [J]. CANCER JOURNAL, 2012, 18 (01): : 45 - 50
  • [5] Antiangiogenic virotherapy: VB-111 targeting glioma
    Khagi, Simon
    Peters, Katherine B.
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (11): : 1099 - 1103
  • [6] Phase 2 study of VB-111, an anti-cancer gene therapy, as monotherapy followed by combination of VB-111 with bevacizumab, in patients with recurrent glioblastoma
    Brenner, A.
    Cohen, Y.
    Vredenburgh, J.
    Peters, K.
    Nayak, L.
    Blumenthal, D.
    Bokstein, F.
    Breitbart, E.
    Bangio, L.
    Sher, N.
    Harats, D.
    Wen, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S584 - S584
  • [7] Bevacizumab antiangiogenic therapy for glioblastoma
    Junck, Larry
    [J]. NEUROLOGY, 2011, 76 (05) : 414 - 415
  • [8] New perspectives in glioblastoma antiangiogenic therapy
    Popescu, Alisa Madalina
    Purcaru, Stefana Oana
    Alexandru, Oana
    Dricu, Anica
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2016, 20 (02): : 109 - 118
  • [9] Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study
    Brenner, Andrew J.
    Peters, Katherine B.
    Vredenburgh, James
    Bokstein, Felix
    Blumenthal, Deborah T.
    Yust-Katz, Shlomit
    Peretz, Idit
    Oberman, Bernice
    Freedman, Laurence S.
    Ellingson, Benjamin M.
    Cloughesy, Timothy F.
    Sher, Naamit
    Cohen, Yael C.
    Lowenton-Spier, Noa
    Minei, Tamar Rachmilewitz
    Yakov, Niva
    Mendel, Itzhak
    Breitbart, Eyal
    Wen, Patrick Y.
    [J]. NEURO-ONCOLOGY, 2020, 22 (05) : 694 - 704
  • [10] Antiangiogenic gene therapy
    K K W Lau
    R Bicknell
    [J]. Gene Therapy, 1999, 6 : 1793 - 1795
12345